Novel Bleeding Risk Score for Patients with Atrial Fibrillation on Oral Anticoagulants, including Direct Oral Anticoagulants.

Adam, Luise; Feller, Martin; Syrogiannouli, Lamprini; Del Giovane, Cinzia; Donzé, Jacques; Baumgartner, Christine; Segna, Daniel; Floriani, Carmen; Roten, Laurent; Fischer, Urs; Aeschbacher, Stefanie; Moschovitis, Giorgio; Schläpfer, Jürg; Shah, Dipen; Amman, Peter; Kobza, Richard; Schwenkglenks, Matthias; Kühne, Michael; Bonati, Leo; Beer, Jürg; ... (2021). Novel Bleeding Risk Score for Patients with Atrial Fibrillation on Oral Anticoagulants, including Direct Oral Anticoagulants. Journal of thrombosis and haemostasis, 19(4), pp. 931-940. Blackwell 10.1111/jth.15251

[img]
Preview
Text
Adam_JThrombHaemost_2021_AAM.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (11MB) | Preview
[img] Text
Adam_JThrombHaemost_2021.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (577kB)

OBJECTIVE

Balancing bleeding risk and stroke risk in patients with atrial fibrillation (AF) is a common challenge. Though several bleeding risk scores exist, most have not included patients on direct oral anticoagulants (DOAC). We aimed at developing a novel bleeding risk score for patients with AF on oral anticoagulants (OAC) including both, vitamin K antagonists (VKA) and DOACs.

METHODS

We included patients with AF on OAC from a prospective multicentre cohort study in Switzerland (SWISS-AF). The outcome was time to first bleeding. Bleeding events were defined as major or clinically relevant non-major bleeding. We used backward elimination to identify bleeding risk variables. We derived the score using a point score system based on the beta coefficients from the multivariable model. We used the Brier score for model calibration (<0.25 indicating good calibration), and Harrel's c-statistics for model discrimination. .

RESULTS

We included 2,147 patients with AF on OAC (72.5% male, mean age 73.4 ± 8.2 years), of whom 1209 (56.3%) took DOAC. After a follow-up of totally 4.4. years, a total of 255 (11.9%) bleeding events occurred. After backward elimination, age>75 years, history of cancer, prior major haemorrhage and arterial hypertension remained in the final prediction model. The Brier score was 0.23 (95% CI 0.19- 0.27), the c-statistics at 12 months was 0.71 (95%CI 0.63 - 0.80).

CONCLUSION

In this prospective cohort study of AF patients and predominantly DOAC users, we successfully derived a bleeding risk prediction model with good calibration and discrimination.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine > Centre of Competence for General Internal Medicine
04 Faculty of Medicine > Medical Education > Institute of General Practice and Primary Care (BIHAM)
04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology

UniBE Contributor:

Adam, Luise Leonore, Feller, Martin, Syrogiannouli, Lamprini, Del Giovane, Cinzia, Donzé, Jacques, Baumgartner, Christine, Segna, Daniel, Floriani, Carmen, Roten, Laurent, Fischer, Urs Martin, Aujesky, Drahomir, Rodondi, Nicolas

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

1538-7933

Publisher:

Blackwell

Funders:

[116] Swiss Heart Foundation = Schweizerische Herzstiftung ; [4] Swiss National Science Foundation

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

11 Feb 2021 11:10

Last Modified:

02 Mar 2023 23:34

Publisher DOI:

10.1111/jth.15251

PubMed ID:

33501722

Uncontrolled Keywords:

SWISS-AF atrial fibrillation bleeding risk direct oral anticoagulants oral anticoagulants

BORIS DOI:

10.48350/152150

URI:

https://boris.unibe.ch/id/eprint/152150

Actions (login required)

Edit item Edit item
Provide Feedback